Baxter International Inc vs Trade Desk Inc — how do they compare? Baxter International Inc trades at $27.61 (market cap $14.36B), while Trade Desk Inc trades at $13.54 (market cap $6.29B). The key difference: Baxter International Inc is far larger — about 2.3× Trade Desk Inc's market cap, and Baxter International Inc pays a 0.14% dividend while Trade Desk Inc pays none. Which is the better fit depends on your goals.
| BAX | TTD | |
|---|---|---|
Market Cap | $14.36B | $6.29B |
Sector | Health | Technology |
52-Week High | $28.35 | $55.36 |
52-Week Low | $15.80 | $13.39 |
Enterprise Value | $21.88B | $5.24B |
Dividend Yield | 0.14% | — |
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $27.55, up 2.0% today, showing strong momentum after recent earnings beats. The stock is approaching its 52-week high of $29.35, with technical indicators signaling bullish momentum. Fundamentally, the company reported Q2 2026 earnings of $0.56 per share, beating estimates, and raised full-year guidance, though profitability metrics remain negative with a -9.27% net income margin. Recent news highlights operational improvements and strong demand for IV solutions.
The outlook is cautiously optimistic as Baxter demonstrates turnaround progress with raised guidance and earnings beats. Investment opportunity lies in continued operational execution and margin recovery, but risks include persistent negative profitability, high debt levels, and competitive pressures in the medtech space. Wall Street sentiment is mixed with 42% buy ratings but a consensus price target below current levels.
The Trade Desk (TTD) is trading at $13.80, down 21.9% in 24 hours and near 7-year lows following disappointing Q2 earnings. Revenue grew just 3% to $715 million, missing guidance, while Q3 guidance projects a 12% decline. Technical indicators show bearish momentum with support at $13 and resistance at $15. Despite strong profitability metrics including 76.9% gross margins, recent execution gaps and advertiser pressure have triggered multiple analyst downgrades.
The outlook remains challenging with near-term revenue headwinds and competitive pressures. While valuation appears reasonable at 16.4x P/E, the stock faces significant execution risks and sentiment deterioration. Recovery depends on stabilizing advertiser relationships and reversing recent market share losses in the ad-tech sector.
Trailing returns across standard periods
Latest headlines on both assets
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →